Porcine rotavirus strain, inactivated vaccine prepared from porcine rotavirus strain and application of porcine rotavirus strain

A porcine rotavirus, rotavirus technology, applied in the direction of viruses, vaccines, antiviral agents, etc., can solve the problems of low antibody level and weak immunity, and achieve the effect of good safety and good commercial development prospects.

CN113186170AActive Publication Date: 2021-07-30SOUTHWEST UNIVERSITY FOR NATIONALITIES
11 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2021-07-30

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a porcine rotavirus strain as well as an inactivated vaccine prepared from the porcine rotavirus strain and application of the porcine rotavirus strain, and firstly discloses a separated porcine A-type rotavirus RVA / Pig-tc / CHN / SCMY-A3 / 2017 / G9P [23] type strain (A3 strain for short), the microbial preservation number of the strain being V202132. The invention also discloses a preparation method of the porcine rotavirus inactivated vaccine, which comprises the following steps: mixing the virus liquid containing the A3 strain with the inactivating agent, inactivating the strain, and mixing the strain with the adjuvant to obtain the porcine rotavirus inactivated vaccine. The inactivated vaccine prepared from the separated porcine rotavirus can generate a higher antibody level and can resist the attack of virus strains.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of preparation of inactivated vaccines, in particular to a strain of porcine rotavirus and the prepared inactivated vaccine and its application. Background technique

[0002] Group A rotavirus (Group A rotavirus, RVA) belongs to Reoviridae (Reoviridae), Rotavirus (Rotavirus), is a non-enveloped double-stranded RNA virus. RVA is an important zoonotic virus and one of the important pathogens causing diarrhea in infants and young animals worldwide, causing great economic losses. Initially, RVA was considered to be host-specific, but now more and more epidemiological data show that RVA can be transmitted from animals to humans, or from one animal to another. Porcine group A rotavirus is an important pathogen that causes severe diarrhea in piglets. The infected piglets mainly show symptoms such as diarrhea, dehydration, vomiting, and anorexia. As important structural proteins, VP7 and VP4 determine the G-type and P-type ...

Examples

Embodiment 1

[0040] Isolation and pathogenicity identification of porcine rotavirus strain of embodiment 1

[0041] Isolation of porcine rotavirus strains

[0042] Take an appropriate amount of stool sample and PBS buffer, mix and vortex according to the ratio of 1:10, freeze and thaw repeatedly three times, absorb the supernatant after centrifugation, filter and sterilize with a filter with a diameter of 0.22 μm. Treated samples were treated with trypsin (TPCK trypsin) at a final concentration of 30 μg / mL at 37°C, 5% CO 2 Under the conditions of 1h, inoculated in a single layer of MA-104 cells, placed in 37 ° C, 5% CO 2 Cultivate in an incubator, observe the state of the cells, and place the cell culture in a -80°C refrigerator for rapid freezing until the cytopathic pathology (CPE) reaches about 80%. After repeated freezing and thawing for 3 times, the supernatant virus liquid is harvested by centrifugation. The virus liquid was purified three times by plaque technique. The isolated s...

Embodiment 2

[0061] The preparation of embodiment 2 porcine rotavirus strain inactivated vaccines

[0062] 1. Method

[0063] (1) Preparation of porcine G9 RVA virus liquid

[0064] First, the purified A3 isolate was treated with trypsin (TPCK trypsin) at a final concentration of 30 μg / mL at 37°C, 5% CO 2 Under the condition of 1h, inoculated in MA-104 cells, 37 ℃, 5% CO 2 Incubate in the incubator for 1 hour, shake once every 20 minutes; discard the suspension after incubation, add 35-40mL maintenance solution (DMEM containing 1% double antibody) at the same time, place at 37°C, 5% CO 2 Cultivate in an incubator; observe the cell state every day until the cell pathological change (CPE) reaches about 80%, place the cell culture in a -80°C refrigerator to freeze rapidly, and after repeated freezing and thawing for 3 times, centrifuge to harvest the supernatant virus liquid and multiply the virus liquid to 100mL for later use.

[0065] (2) Condition optimization of inactivator

[0066] ...